The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

As with PTSD, people develop acute stress disorder after exposure to traumatic events. The key difference in the diagnostic ...

Extracorporeal therapy (ECT) is a method of blood purification performed to remove a pathogenic substance, or solute, from ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

The following is a summary of “Critically ill adult patients with acute leukemia: a systematic review and meta-analysis,” published in the January 2025 issue of Critical Care by Chean et al. Researche ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

PhD Defense: Clinical Outcome after Cellular Therapies in Children with Acute Leukemia; the Bumpy Road to Recovery ...

Mayo Clinic has joined SeaStar Medical as the 15th site authorised to enrol subjects for the company’s pivotal NEUTRALIZE-AKI ...